Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in J Neurol Retrieve available abstracts of 289 articles: HTML format

Single Articles

June 2025
1. CHEN H
   A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
   J Neurol. 2025;272:445.
   PubMed     Abstract available
   
   
   
2. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
   Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
   J Neurol. 2025;272:444.
   PubMed    
   
   
   
3. GERAN R, Steiner OL, Krasivskaya E, Hannemann U, et al
   Inverse relation between serum neurofilament light chain and cognitive function in chronic inflammatory demyelinating polyneuropathy.
   J Neurol. 2025;272:439.
   PubMed     Abstract available
   
   
   May 2025
4. MACCORA S, Vinciguerra C, Messina C, Bevilacqua L, et al
   Double seronegative myasthenia gravis and mimics: a retrospective cross-sectional study by two tertiary centers in the Southern Italy.
   J Neurol. 2025;272:433.
   PubMed     Abstract available
   
   
   
5. NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
   From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
   J Neurol. 2025;272:434.
   PubMed     Abstract available
   
   
   
6. GASPERINI C, Centonze D, Conte A, Gallo P, et al
   Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
   J Neurol. 2025;272:428.
   PubMed     Abstract available
   
   
   
7. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
   Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
   J Neurol. 2025;272:423.
   PubMed    
   
   
   
8. ARZALLUZ-LUQUE J, Dumez P, Picard G, Benaiteau M, et al
   Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
   J Neurol. 2025;272:421.
   PubMed     Abstract available
   
   
   
9. GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
   The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
   J Neurol. 2025;272:420.
   PubMed     Abstract available
   
   
   
10. PIGNOLO A, Vinciguerra C, Monastero R, Rini N, et al
    Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review.
    J Neurol. 2025;272:417.
    PubMed     Abstract available
    
    
    
11. DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al
    Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis.
    J Neurol. 2025;272:415.
    PubMed     Abstract available
    
    
    
12. CAO S, Zhou X, Du J, Zhang J, et al
    Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.
    J Neurol. 2025;272:406.
    PubMed     Abstract available
    
    
    
13. ZHANG Y, Li G, Su H, Liang Y, et al
    Effects of exercise on balance function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:405.
    PubMed     Abstract available
    
    
    
14. GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al
    Beyond EDSS: multidomain impairments are detectable and associated with walking disorders in low-disabled people with multiple sclerosis.
    J Neurol. 2025;272:404.
    PubMed     Abstract available
    
    
    
15. WANG Z, Tan H, Huang W, Fan Y, et al
    Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder.
    J Neurol. 2025;272:403.
    PubMed     Abstract available
    
    
    
16. FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al
    The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
    J Neurol. 2025;272:400.
    PubMed     Abstract available
    
    
    
17. KIM YS, Shin IJ, Park DG, Yoon JH, et al
    Hashimoto's encephalopathy with diffuse leukoencephalopathy: serial MRI and gait analysis.
    J Neurol. 2025;272:399.
    PubMed    
    
    
    
18. ROSSINI E, Di Stefano V, Iorio R, Habetswallner F, et al
    Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.
    J Neurol. 2025;272:396.
    PubMed     Abstract available
    
    
    
19. TARANU D, Balz LT, Holbrook J, Tumani V, et al
    Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.
    J Neurol. 2025;272:398.
    PubMed     Abstract available
    
    
    
20. ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al
    Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
    J Neurol. 2025;272:388.
    PubMed     Abstract available
    
    
    
21. HU S, Liao Z, Wang R, Zhang M, et al
    Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.
    J Neurol. 2025;272:387.
    PubMed     Abstract available
    
    
    
22. FILIPPI M, Preziosa P, Rocca MA
    Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy.
    J Neurol. 2025;272:385.
    PubMed    
    
    
    
23. ROY S, Huang Y, Hu C, Fitzgerald KC, et al
    Core diagnostic features of stiff person syndrome: insights from a case-control study.
    J Neurol. 2025;272:377.
    PubMed     Abstract available
    
    
    
24. FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
    Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
    J Neurol. 2025;272:375.
    PubMed     Abstract available
    
    
    
25. KOLB H, Shachaf Y, Fainberg K, Golan M, et al
    Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
    J Neurol. 2025;272:374.
    PubMed     Abstract available
    
    
    
26. HERMAN D, Tanniou J, Leray E, Pierret C, et al
    Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.
    J Neurol. 2025;272:371.
    PubMed     Abstract available
    
    
    
27. KUUTTI K, Laakso SM, Viitala M, Atula S, et al
    Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.
    J Neurol. 2025;272:370.
    PubMed     Abstract available
    
    
    April 2025
28. CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al
    Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis.
    J Neurol. 2025;272:367.
    PubMed    
    
    
    
29. PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
    Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    J Neurol. 2025;272:366.
    PubMed    
    
    
    
30. SEERY N, Wesselingh R, Beech P, Broadley J, et al
    Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study.
    J Neurol. 2025;272:361.
    PubMed     Abstract available
    
    
    
31. MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
    Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
    J Neurol. 2025;272:358.
    PubMed     Abstract available
    
    
    
32. CAMPETELLA L, Smolik K, Farina A, Joubert B, et al
    Neurodegeneration and the immune system: lessons from autoimmune encephalitis.
    J Neurol. 2025;272:359.
    PubMed     Abstract available
    
    
    
33. SIRIRATNAM P, Huda S, Van der Walt A, Sanfilippo P, et al
    Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
    J Neurol. 2025;272:339.
    PubMed     Abstract available
    
    
    
34. LEAVITT V, Mostert J, Comtois J, Moral E, et al
    Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
    J Neurol. 2025;272:338.
    PubMed     Abstract available
    
    
    
35. BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al
    Correction: Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:337.
    PubMed    
    
    
    
36. OJHA A, Tommasin S, Piervincenzi C, Baione V, et al
    Clinical and MRI features contributing to the clinico-radiological dissociation in a large cohort of people with multiple sclerosis.
    J Neurol. 2025;272:327.
    PubMed     Abstract available
    
    
    
37. HONG J, Gaubert M, Lefort M, Ferre JC, et al
    Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.
    J Neurol. 2025;272:316.
    PubMed     Abstract available
    
    
    
38. MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al
    Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2025;272:314.
    PubMed     Abstract available
    
    
    
39. LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al
    Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.
    J Neurol. 2025;272:302.
    PubMed     Abstract available
    
    
    March 2025
40. KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al
    MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
    J Neurol. 2025;272:294.
    PubMed     Abstract available
    
    
    
41. KHERBEK H, Paramasivan NK, Dasari S, Karsten C, et al
    Exploring autoantigens in autoimmune limbic encephalitis using phage immunoprecipitation sequencing.
    J Neurol. 2025;272:292.
    PubMed     Abstract available
    
    
    
42. RITTEL JC, Hudasch D, Doppler K, Bergh FT, et al
    Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.
    J Neurol. 2025;272:287.
    PubMed     Abstract available
    
    
    
43. LADEIRA F, Nobrega C, Cerqueira J
    Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
    J Neurol. 2025;272:288.
    PubMed     Abstract available
    
    
    
44. FUJII S, Yaguchi H, Kudo A, Eguchi K, et al
    Autoimmune cerebellar ataxia with Kelch-like protein 11 antibodies in a large cohort study.
    J Neurol. 2025;272:282.
    PubMed    
    
    
    
45. FARINA A, Villagran-Garcia M, Abichou-Klich A, Benaiteau M, et al
    Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort.
    J Neurol. 2025;272:273.
    PubMed     Abstract available
    
    
    
46. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.
    J Neurol. 2025;272:275.
    PubMed     Abstract available
    
    
    
47. DING Y, Wu D, Chu H, Tang Y, et al
    Clinical characterization of diseases associated with anti-N-methyl-D-aspartate receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein antibodies in adults.
    J Neurol. 2025;272:262.
    PubMed     Abstract available
    
    
    
48. SORENSEN NV, Nilsson AC, Dos AH, Stenor CM, et al
    Anti-GFAP associated opsoclonus-myoclonus-ataxia syndrome in a patient with multiple autoimmune comorbidities-a case report.
    J Neurol. 2025;272:263.
    PubMed    
    
    
    
49. KOMATSU T, Motegi H, Mimori M, Okumura M, et al
    Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy.
    J Neurol. 2025;272:243.
    PubMed     Abstract available
    
    
    
50. BOSTAN M, Li C, Cheong JW, Wong DWK, et al
    Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.
    J Neurol. 2025;272:237.
    PubMed     Abstract available
    
    
    February 2025
51. AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al
    Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.
    J Neurol. 2025;272:228.
    PubMed     Abstract available
    
    
    
52. PARAMASIVAN NK, Sarker P, Zekeridou A, Staff NP, et al
    Upper motor neuron-predominant motor neuron disease: a novel immunotherapy-responsive association of GAD65 autoimmunity.
    J Neurol. 2025;272:230.
    PubMed     Abstract available
    
    
    
53. BINKS SNM, Morse IM, Ashraghi M, Vincent A, et al
    Myasthenia gravis in 2025: five new things and four hopes for the future.
    J Neurol. 2025;272:226.
    PubMed     Abstract available
    
    
    
54. SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al
    Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.
    J Neurol. 2025;272:217.
    PubMed     Abstract available
    
    
    
55. BALSHI A, Dempsey J, Manning N, Leuenberger G, et al
    A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.
    J Neurol. 2025;272:223.
    PubMed     Abstract available
    
    
    
56. NAYAK S, Wagshul ME, Foley FW, Motl RW, et al
    Associations between connectivity in functional brain networks and gait speed in older adults with and without multiple sclerosis.
    J Neurol. 2025;272:216.
    PubMed     Abstract available
    
    
    
57. DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al
    CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.
    J Neurol. 2025;272:211.
    PubMed     Abstract available
    
    
    
58. MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al
    Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bands.
    J Neurol. 2025;272:207.
    PubMed     Abstract available
    
    
    
59. NISHIMORI Y, Tanboon J, Oyama M, Motegi H, et al
    Anti-mitochondrial M2 antibody-positive myositis may be an independent subtype of autoimmune myositis.
    J Neurol. 2025;272:206.
    PubMed     Abstract available
    
    
    
60. CHEN X, Wang R, Li R, Hu S, et al
    A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder.
    J Neurol. 2025;272:194.
    PubMed     Abstract available
    
    
    
61. FILIPPI M, Amato MP, Avolio C, Gallo P, et al
    Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.
    J Neurol. 2025;272:179.
    PubMed     Abstract available
    
    
    
62. HANSEL M, Reichmann H, Haehner A, Schmitz-Peiffer H, et al
    Hippocampal dysfunction after autoimmune encephalitis depending on the antibody type.
    J Neurol. 2025;272:175.
    PubMed     Abstract available
    
    
    January 2025
63. GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al
    Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
    J Neurol. 2025;272:162.
    PubMed     Abstract available
    
    
    
64. DE ARMAS FERNANDEZ JR, Garcia CEP, Herrera BA, Garcia FD, et al
    Incidence of Guillain-Barre syndrome in Cuba before and during the Oropouche virus emergency, 2018-2024.
    J Neurol. 2025;272:164.
    PubMed    
    
    
    
65. BOAVENTURA M, Fragoso DC, Avolio I, Pereira SA, et al
    Brain tissue integrity in neuromyelitis optica spectrum disorder through T1-w/T2-w ratio, MTR and DTI.
    J Neurol. 2025;272:157.
    PubMed     Abstract available
    
    
    
66. INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al
    Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
    J Neurol. 2025;272:153.
    PubMed     Abstract available
    
    
    
67. PIHL-JENSEN G, Frederiksen JL
    The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.
    J Neurol. 2025;272:131.
    PubMed     Abstract available
    
    
    
68. LAGEMAN SB, Jolly A, Sahi N, Prados F, et al
    Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis.
    J Neurol. 2025;272:142.
    PubMed     Abstract available
    
    
    
69. MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al
    Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.
    J Neurol. 2025;272:141.
    PubMed     Abstract available
    
    
    
70. BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al
    Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:151.
    PubMed     Abstract available
    
    
    
71. MAR S, Valeriani M, Steinborn B, Schreiner T, et al
    Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
    J Neurol. 2025;272:137.
    PubMed     Abstract available
    
    
    
72. MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al
    BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients.
    J Neurol. 2025;272:147.
    PubMed     Abstract available
    
    
    
73. PREZIOSA P, Pagani E, Meani A, Margoni M, et al
    Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign lesions in multiple sclerosis.
    J Neurol. 2025;272:145.
    PubMed     Abstract available
    
    
    
74. PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al
    CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.
    J Neurol. 2025;272:119.
    PubMed     Abstract available
    
    
    
75. ZANGHI A, Greco A, Giancipoli E, Tumani H, et al
    Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
    J Neurol. 2025;272:109.
    PubMed     Abstract available
    
    
    
76. FOCKE JK, Brokbals M, Becker J, Veltkamp R, et al
    Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review.
    J Neurol. 2025;272:135.
    PubMed     Abstract available
    
    
    
77. LIU M, Ren H, Yao D, Yao M, et al
    Autoimmune cerebellar ataxia associated with anti-SEZ6L2 antibody: report of three cases.
    J Neurol. 2025;272:127.
    PubMed    
    
    
    
78. ROBERTSON NP
    Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
    J Neurol. 2025;272:106.
    PubMed     Abstract available
    
    
    
79. FAROOQI AM, Sawalha A, Omidi SJ, Dubey D, et al
    Seizures and status epilepticus in anti-NMDA receptor encephalitis.
    J Neurol. 2025;272:95.
    PubMed     Abstract available
    
    
    
80. WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al
    Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.
    J Neurol. 2025;272:93.
    PubMed     Abstract available
    
    
    
81. FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al
    Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
    J Neurol. 2025;272:96.
    PubMed     Abstract available
    
    
    
82. SCHUMACHER A, Hieke A, Spenner M, Schmitz F, et al
    Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry.
    J Neurol. 2025;272:100.
    PubMed     Abstract available
    
    
    December 2024
83. NICOLESCU M, Haussler V, Paul F, Oertel FC, et al
    Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
    J Neurol. 2024;272:86.
    PubMed     Abstract available
    
    
    
84. BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al
    CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
    J Neurol. 2024;272:85.
    PubMed     Abstract available
    
    
    
85. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    J Neurol. 2024;272:77.
    PubMed     Abstract available
    
    
    
86. INAN B, Ozturk B, Ata N, Ulgu MM, et al
    A nationwide epidemiological study of myasthenia gravis in Turkey.
    J Neurol. 2024;272:5.
    PubMed     Abstract available
    
    
    
87. VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al
    Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis.
    J Neurol. 2024;272:30.
    PubMed     Abstract available
    
    
    
88. PONZIO M, Santoni L, Molina M, Tavazzi E, et al
    Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.
    J Neurol. 2024;272:50.
    PubMed     Abstract available
    
    
    
89. DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al
    Spasticity patterns assessment and recognition for therapeutic approaches (SPARTA) in multiple sclerosis: a multicenter epidemiological study.
    J Neurol. 2024;272:34.
    PubMed     Abstract available
    
    
    
90. KLIMAS R, Sturm D, Altenborg A, Stylianou N, et al
    Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy.
    J Neurol. 2024;272:51.
    PubMed     Abstract available
    
    
    
91. BUGGE C, Engebretsen I, Kristiansen IS, Saether EM, et al
    Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - a register-based study.
    J Neurol. 2024;272:15.
    PubMed     Abstract available
    
    
    
92. FASANO C, Bettiol A, Vastola M, Lotti A, et al
    Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study.
    J Neurol. 2024;272:13.
    PubMed     Abstract available
    
    
    
93. GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al
    Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
    J Neurol. 2024;272:27.
    PubMed     Abstract available
    
    
    
94. COMABELLA M, Hegen H, Villar LM, Rejdak K, et al
    Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
    J Neurol. 2024;272:26.
    PubMed     Abstract available
    
    
    
95. MARLET IR, Andersen RK, Axelsen KH, Andersen LK, et al
    Factors affecting the diagnostic delay of myasthenia gravis.
    J Neurol. 2024;272:29.
    PubMed     Abstract available
    
    
    
96. FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al
    Disability worsening outcome in multiple sclerosis based on EDSS: does half a point matter?
    J Neurol. 2024;272:9.
    PubMed    
    
    
    November 2024
97. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Rapid differentiation of MOGAD and MS after a single optic neuritis.
    J Neurol. 2024;271:7222-7231.
    PubMed     Abstract available
    
    
    October 2024
98. FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al
    Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715.
    PubMed     Abstract available
    
    
    
99. TARD C, Laforet P, de Pouvourville G, Crochard A, et al
    Treatment of myasthenia gravis in france: A retrospective claims database study (STAMINA).
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12714.
    PubMed     Abstract available
    
    
    
100. MOSER T, Gruber J, Mylonaki E, Bohm V, et al
     Autoimmune and infectious encephalitis: development of a discriminative tool for early diagnosis and initiation of therapy.
     J Neurol. 2024 Oct 5. doi: 10.1007/s00415-024-12712.
     PubMed     Abstract available
     
     
     
101. BALCK A, Lange LM, Neumann A, Royl G, et al
     Highly beneficial outcome in severe acute necrotizing encephalopathy with tocilizumab treatment.
     J Neurol. 2024;271:7042-7045.
     PubMed    
     
     
     
102. SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al
     MS treatment de-escalation: review and commentary.
     J Neurol. 2024;271:6426-6438.
     PubMed     Abstract available
     
     
     September 2024
103. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
     In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
     J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701.
     PubMed     Abstract available
     
     
     
104. PEKMEZOVIC T, Jovicevic V, Andabaka M, Momcilovic N, et al
     Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: population-based registry data.
     J Neurol. 2024 Sep 22. doi: 10.1007/s00415-024-12698.
     PubMed     Abstract available
     
     
     
105. MARGONI M, Valsasina P, Moiola L, Mistri D, et al
     Monoaminergic network abnormalities are associated with fatigue in pediatric multiple sclerosis.
     J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689.
     PubMed     Abstract available
     
     
     
106. MENG H, He L, Chunyu H, Zhou Q, et al
     (18)F-DPA714 PET/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study.
     J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12690.
     PubMed     Abstract available
     
     
     
107. MANGIORIS G, Orozco E, Dubey D, Flanagan EP, et al
     Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study.
     J Neurol. 2024 Sep 15. doi: 10.1007/s00415-024-12680.
     PubMed     Abstract available
     
     
     
108. KONITSIOTI AM, Pruss H, Laurent S, Fink GR, et al
     Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.
     J Neurol. 2024 Sep 14. doi: 10.1007/s00415-024-12642.
     PubMed     Abstract available
     
     
     
109. YOUSEF H, Malagurski Tortei B, Castiglione F
     Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.
     J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651.
     PubMed     Abstract available
     
     
     
110. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
     Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
     J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608.
     PubMed     Abstract available
     
     
     
111. HAFSTEINSDOTTIR B, Farman H, Lagerstrom N, Zetterberg H, et al
     Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barre syndrome.
     J Neurol. 2024 Sep 9. doi: 10.1007/s00415-024-12679.
     PubMed     Abstract available
     
     
     
112. CALLEN AM, Zurawski J, Chu R, Tie Y, et al
     The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in relapsing-remitting multiple sclerosis.
     J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656.
     PubMed     Abstract available
     
     
     
113. DELUCA J
     Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat it?
     J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630.
     PubMed    
     
     
     
114. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
     Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
     J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627.
     PubMed    
     
     
     
115. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
     Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
     J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560.
     PubMed    
     
     
     
116. SHI Z, Kong L, Wang R, Wang X, et al
     Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder.
     J Neurol. 2024;271:6089-6095.
     PubMed     Abstract available
     
     
     
117. QUINT P, Schroeter CB, Kohle F, Ozturk M, et al
     Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.
     J Neurol. 2024;271:5930-5943.
     PubMed     Abstract available
     
     
     
118. HECHLER A, Kuchling J, Muller-Jensen L, Klag J, et al
     Hippocampal hub failure is linked to long-term memory impairment in anti-NMDA-receptor encephalitis: insights from structural connectome graph theoretical network analysis.
     J Neurol. 2024;271:5886-5898.
     PubMed     Abstract available
     
     
     
119. ABBOUD H, Sun R, Modak N, Elkasaby M, et al
     Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study.
     J Neurol. 2024;271:5875-5885.
     PubMed     Abstract available
     
     
     August 2024
120. WURDACK K, Pruss H, Finke C
     Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report.
     J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659.
     PubMed     Abstract available
     
     
     
121. CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al
     Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).
     J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621.
     PubMed     Abstract available
     
     
     
122. BAYAT M, Harbo T, Anzabi M, Bayat A, et al
     POLG-related mitochondrial disease mimicking autoimmune encephalitis.
     J Neurol. 2024 Aug 24. doi: 10.1007/s00415-024-12641.
     PubMed    
     
     
     
123. CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al
     Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
     J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610.
     PubMed     Abstract available
     
     
     
124. SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al
     Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
     J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638.
     PubMed     Abstract available
     
     
     
125. MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al
     The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
     J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622.
     PubMed     Abstract available
     
     
     
126. DUMEZ P, Villagran-Garcia M, Bani-Sadr A, Benaiteau M, et al
     Specific clinical and radiological characteristics of anti-NMDA receptor autoimmune encephalitis following herpes encephalitis.
     J Neurol. 2024 Aug 16. doi: 10.1007/s00415-024-12615.
     PubMed     Abstract available
     
     
     
127. KOKUBUN N, Tsuchiya T, Hamaguchi M, Ueda Y, et al
     IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies.
     J Neurol. 2024 Aug 2. doi: 10.1007/s00415-024-12597.
     PubMed     Abstract available
     
     
     
128. ARNETT S, Chew SH, Leitner U, Hor JY, et al
     Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
     J Neurol. 2024;271:4794-4812.
     PubMed     Abstract available
     
     
     
129. ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al
     Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.
     J Neurol. 2024;271:5275-5289.
     PubMed     Abstract available
     
     
     
130. KLIMAS R, Kordes A, Huckemann S, Gasz Z, et al
     The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected immune neuropathies.
     J Neurol. 2024;271:5109-5121.
     PubMed     Abstract available
     
     
     
131. RECHTMAN A, Freidman-Korn T, Zveik O, Shweiki L, et al
     Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings.
     J Neurol. 2024;271:5102-5108.
     PubMed     Abstract available
     
     
     
132. ZHANG L, Zhang Y, Li R, Zhu J, et al
     Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.
     J Neurol. 2024;271:4991-5002.
     PubMed     Abstract available
     
     
     
133. COLY M, Adams D, Attarian S, Bouhour F, et al
     Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome.
     J Neurol. 2024;271:4982-4990.
     PubMed     Abstract available
     
     
     
134. ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al
     Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
     J Neurol. 2024;271:4949-4962.
     PubMed     Abstract available
     
     
     July 2024
135. PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
     A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
     J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12588.
     PubMed     Abstract available
     
     
     
136. PAPATHANASIOU A, Tench CR, Ambrose PA, Sedehizadeh S, et al
     Pre-thymectomy disease severity predicts outcome in acetylcholine receptor antibody-positive generalised myasthenia gravis.
     J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12592.
     PubMed     Abstract available
     
     
     
137. FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al
     Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
     J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590.
     PubMed     Abstract available
     
     
     
138. MANZANO GS, Levy M, Salky R, Mateen FJ, et al
     Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
     J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585.
     PubMed     Abstract available
     
     
     
139. MITOMA H, Manto M
     Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.
     J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12596.
     PubMed     Abstract available
     
     
     
140. PASSALI M, Galea I, Knudsen MH, Lau LC, et al
     Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.
     J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587.
     PubMed     Abstract available
     
     
     
141. HABIB AA, Klink AJ, Muppidi S, Parthan A, et al
     United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.
     J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12569.
     PubMed     Abstract available
     
     
     
142. KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al
     Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
     J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581.
     PubMed     Abstract available
     
     
     
143. MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
     Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
     J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
     PubMed     Abstract available
     
     
     
144. RAVANO V, Andelova M, Piredda GF, Sommer S, et al
     Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
     J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
     PubMed     Abstract available
     
     
     
145. VITI V, Zanetta C, Capra R, Municchi A, et al
     Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
     J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
     PubMed    
     
     
     
146. ZHU F, Wang WF, Ma CH, Liang H, et al
     Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.
     J Neurol. 2024 Jul 9. doi: 10.1007/s00415-024-12556.
     PubMed     Abstract available
     
     
     
147. DELUCA J
     Fatigue in multiple sclerosis: can we measure it and can we treat it?
     J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524.
     PubMed     Abstract available
     
     
     
148. ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al
     Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
     J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542.
     PubMed    
     
     
     
149. PREZIOSA P, Amato MP, Battistini L, Capobianco M, et al
     Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
     J Neurol. 2024;271:3879-3896.
     PubMed     Abstract available
     
     
     
150. KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
     Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
     J Neurol. 2024;271:4599-4609.
     PubMed     Abstract available
     
     
     
151. ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
     Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
     J Neurol. 2024;271:4495-4502.
     PubMed     Abstract available
     
     
     
152. WANG R, Sun D, Wang X, Shi Z, et al
     Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
     J Neurol. 2024;271:4503-4512.
     PubMed     Abstract available
     
     
     
153. HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
     ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
     J Neurol. 2024;271:4348-4360.
     PubMed     Abstract available
     
     
     
154. PESTCHANKER C, Bertado Cortez B, Lana Peixoto MA, Gortari JI, et al
     Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
     J Neurol. 2024;271:4292-4299.
     PubMed     Abstract available
     
     
     
155. MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
     The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
     J Neurol. 2024;271:4019-4027.
     PubMed     Abstract available
     
     
     June 2024
156. LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
     A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
     J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
     PubMed     Abstract available
     
     
     
157. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
     Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigms.
     J Neurol. 2024 Jun 25. doi: 10.1007/s00415-024-12520.
     PubMed     Abstract available
     
     
     
158. NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
     Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
     J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
     PubMed     Abstract available
     
     
     
159. SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al
     Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
     J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517.
     PubMed     Abstract available
     
     
     
160. FUNKE M, Eveslage M, Zschuntzsch J, Hagenacker T, et al
     Fatigue and associated factors in myasthenia gravis: a nationwide registry study.
     J Neurol. 2024 Jun 13. doi: 10.1007/s00415-024-12490.
     PubMed     Abstract available
     
     
     
161. YU H, Wang X, Pan Y, Li H, et al
     Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
     J Neurol. 2024 Jun 12. doi: 10.1007/s00415-024-12494.
     PubMed     Abstract available
     
     
     
162. KONG X, Guo K, Liu X, Gong X, et al
     Differentiation between viral and autoimmune limbic encephalitis: a prospective cohort study with development and validation of a diagnostic model.
     J Neurol. 2024 Jun 11. doi: 10.1007/s00415-024-12468.
     PubMed     Abstract available
     
     
     
163. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
     Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
     J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472.
     PubMed     Abstract available
     
     
     
164. MUCK A, Pfeuffer S, Mir L, Genau S, et al
     Myasthenic crises are associated with negative long-term outcomes in myasthenia gravis.
     J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12478.
     PubMed    
     
     
     
165. HERAUD C, Bresch S, Landes-Chateau C, Bourg V, et al
     Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis.
     J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12454.
     PubMed     Abstract available
     
     
     
166. STARK AJ, Mobley BC, Eaton JE
     Progressive leukoencephalopathy as a manifestation of primary angiitis of the central nervous system: case report and review of the literature.
     J Neurol. 2024;271:3648-3652.
     PubMed     Abstract available
     
     
     May 2024
167. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
     Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
     J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448.
     PubMed     Abstract available
     
     
     
168. HUANG W, Zhang H, Li X, Zhang J, et al
     Prognostic factors underlying the development of drug-resistant epilepsy in patients with autoimmune encephalitis: a retrospective cohort study.
     J Neurol. 2024 May 27. doi: 10.1007/s00415-024-12432.
     PubMed     Abstract available
     
     
     
169. CHAE J, Nguyen TT, Oh SY
     Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis.
     J Neurol. 2024 May 26. doi: 10.1007/s00415-024-12461.
     PubMed     Abstract available
     
     
     
170. MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
     The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
     J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
     PubMed     Abstract available
     
     
     
171. FJORDSIDE L, Nissen MS, Florescu AM, Storgaard M, et al
     Validation of a risk score to differentiate autoimmune and viral encephalitis: a Nationwide Cohort Study in Denmark.
     J Neurol. 2024 May 18. doi: 10.1007/s00415-024-12392.
     PubMed     Abstract available
     
     
     
172. CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
     Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
     J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
     PubMed     Abstract available
     
     
     
173. WOLF E, Wicklein R, Aly L, Schmaderer C, et al
     Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
     J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
     PubMed     Abstract available
     
     
     
174. FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
     The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
     J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
     PubMed     Abstract available
     
     
     
175. BARDEL B, Creange A, Bonardet N, Bapst B, et al
     Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
     J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
     PubMed     Abstract available
     
     
     
176. GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
     Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
     J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
     PubMed     Abstract available
     
     
     
177. PREZIOSA P, Rocca MA, Filippi M
     Radiologically isolated syndromes: to treat or not to treat?
     J Neurol. 2024;271:2370-2378.
     PubMed     Abstract available
     
     
     
178. LEHNERER S, Herdick M, Stegherr R, Gerischer L, et al
     Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient's perspective.
     J Neurol. 2024;271:2824-2839.
     PubMed     Abstract available
     
     
     
179. KONEN FF, Jendretzky KF, Ratuszny D, Schuppner R, et al
     Ravulizumab in myasthenic crisis: the first case report.
     J Neurol. 2024;271:2898-2901.
     PubMed    
     
     
     
180. BURTON JM, Youn S, Al-Ani A, Costello F, et al
     Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
     J Neurol. 2024;271:2662-2671.
     PubMed     Abstract available
     
     
     
181. HEIDER D, Stetefeld H, Meisel A, Bosel J, et al
     POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis.
     J Neurol. 2024;271:2875-2879.
     PubMed    
     
     
     
182. RISI M, Greco G, Masciocchi S, Rigoni E, et al
     MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment.
     J Neurol. 2024;271:2840-2843.
     PubMed     Abstract available
     
     
     
183. DOUBROVINSKAJA S, Korporal-Kuhnke M, Jarius S, Haas J, et al
     Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
     J Neurol. 2024;271:2866-2870.
     PubMed     Abstract available
     
     
     
184. ROCCA MA, Romano F, Tedone N, Filippi M, et al
     Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
     J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
     PubMed     Abstract available
     
     
     April 2024
185. DIMAURO KA, Swetlik C, Cohen JA
     Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
     J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
     PubMed     Abstract available
     
     
     
186. ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
     Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
     J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
     PubMed     Abstract available
     
     
     
187. FONTE J, Stabile A, de Curtis M, Di Giacomo R, et al
     Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study.
     J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12385.
     PubMed    
     
     
     
188. NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
     Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
     J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
     PubMed     Abstract available
     
     
     
189. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
     Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
     J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
     PubMed     Abstract available
     
     
     
190. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
     Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
     J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
     PubMed     Abstract available
     
     
     
191. SINGER BA, Feng J, Chiong-Rivero H
     Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
     J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
     PubMed     Abstract available
     
     
     
192. ZHANG Y, Liu D, Zhang Z, Huang X, et al
     Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
     J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367.
     PubMed    
     
     
     
193. STALTER J, Pars K, Witt K
     Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
     J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
     PubMed     Abstract available
     
     
     
194. MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al
     Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.
     J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317.
     PubMed     Abstract available
     
     
     
195. CELIK M, Baba C, Irmak C, Ozakbas S, et al
     Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
     J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
     PubMed     Abstract available
     
     
     
196. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
     Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
     J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
     PubMed     Abstract available
     
     
     
197. TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al
     Takotsubo cardiomyopathy in Guillain-Barre syndrome.
     J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295.
     PubMed     Abstract available
     
     
     
198. MAIDA E, Moccia M, Palladino R, Borriello G, et al
     ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
     J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
     PubMed     Abstract available
     
     
     
199. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
     Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
     J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
     PubMed     Abstract available
     
     
     
200. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
     Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
     J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
     PubMed    
     
     
     
201. MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al
     Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
     J Neurol. 2024;271:1707-1716.
     PubMed     Abstract available
     
     
     
202. WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al
     Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.
     J Neurol. 2024;271:1861-1872.
     PubMed     Abstract available
     
     
     
203. TEDONE N, Vizzino C, Meani A, Gallo A, et al
     The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
     J Neurol. 2024;271:1813-1823.
     PubMed     Abstract available
     
     
     
204. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
     Big Multiple Sclerosis Data network: an international registry research network.
     J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
     PubMed     Abstract available
     
     
     
205. HUA T, Fan H, Duan Y, Tian D, et al
     Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
     J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
     PubMed     Abstract available
     
     
     March 2024
206. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
     Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
     J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
     PubMed     Abstract available
     
     
     
207. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
     Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
     J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
     PubMed     Abstract available
     
     
     
208. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
     Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
     J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
     PubMed     Abstract available
     
     
     
209. ZHANG H, Ma J, Feng Y, Ma H, et al
     Efgartigimod in the treatment of Guillain-Barre syndrome.
     J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321.
     PubMed     Abstract available
     
     
     
210. FUCHS L, Shelly S, Vigiser I, Kolb H, et al
     Real-World experience with efgartigimod in patients with myasthenia gravis.
     J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293.
     PubMed     Abstract available
     
     
     
211. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
     Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
     J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
     PubMed     Abstract available
     
     
     
212. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
     Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
     J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238.
     PubMed    
     
     
     
213. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
     Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
     J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
     PubMed     Abstract available
     
     
     
214. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
     Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
     J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
     PubMed     Abstract available
     
     
     
215. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
     Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
     J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
     PubMed    
     
     
     
216. VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al
     Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
     J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252.
     PubMed     Abstract available
     
     
     
217. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
     The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
     J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
     PubMed     Abstract available
     
     
     
218. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
     Sex impacts treatment decisions in multiple sclerosis.
     J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
     PubMed     Abstract available
     
     
     
219. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
     Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
     J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
     PubMed     Abstract available
     
     
     
220. ZID Y, Robertson NP
     Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
     J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
     PubMed    
     
     
     
221. LI J, Wu X, Chu T, Tan X, et al
     The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
     J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247.
     PubMed     Abstract available
     
     
     
222. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
     Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
     J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
     PubMed     Abstract available
     
     
     February 2024
223. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
     Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
     J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
     PubMed     Abstract available
     
     
     
224. TOLJAN K, Briggs FBS
     Male sexual and reproductive health in multiple sclerosis: a scoping review.
     J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
     PubMed     Abstract available
     
     
     
225. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
     A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
     J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
     PubMed     Abstract available
     
     
     
226. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
     Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
     J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
     PubMed     Abstract available
     
     
     
227. NGUYEN TT, Chae J, Kang JJ, Oh SY, et al
     Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
     J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262.
     PubMed    
     
     
     
228. WEISS MD, Freimer M, Leite MI, Maniaol A, et al
     Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
     J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209.
     PubMed     Abstract available
     
     
     
229. OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
     Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
     J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
     PubMed    
     
     
     
230. GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
     Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
     J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
     PubMed     Abstract available
     
     
     
231. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
     Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
     J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
     PubMed    
     
     
     
232. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
     The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
     J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
     PubMed     Abstract available
     
     
     
233. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
     Prodromal multiple sclerosis: considerations and future utility.
     J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
     PubMed     Abstract available
     
     
     
234. VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
     Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
     J Neurol. 2024;271:1019-1022.
     PubMed    
     
     
     January 2024
235. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
     Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
     J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
     PubMed     Abstract available
     
     
     
236. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
     Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
     J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
     PubMed     Abstract available
     
     
     
237. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
     Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
     J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
     PubMed     Abstract available
     
     
     
238. CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
     Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
     J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
     PubMed     Abstract available
     
     
     
239. FENG G, Posa S, Sureshkumar A, Simpson S, et al
     Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
     J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
     PubMed     Abstract available
     
     
     
240. ZHENG P, Sandroff BM, Motl RW
     Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
     J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
     PubMed     Abstract available
     
     
     
241. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
     Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
     J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
     PubMed    
     
     
     
242. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
     Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
     J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
     PubMed     Abstract available
     
     
     
243. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
     Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
     J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
     PubMed     Abstract available
     
     
     
244. FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
     Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
     J Neurol. 2024;271:75-78.
     PubMed    
     
     
     
245. NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
     Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
     J Neurol. 2024;271:564-574.
     PubMed     Abstract available
     
     
     
246. WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
     Neurological manifestation of HEV infection: still a rare disease entity?
     J Neurol. 2024;271:386-394.
     PubMed     Abstract available
     
     
     
247. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
     Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
     J Neurol. 2024;271:374-385.
     PubMed     Abstract available
     
     
     
248. KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
     Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
     J Neurol. 2024;271:141-176.
     PubMed     Abstract available
     
     
     December 2023
249. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
     Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
     J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
     PubMed    
     
     
     
250. LIU M, Ren H, Wang L, Fan S, et al
     Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
     J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
     PubMed     Abstract available
     
     
     
251. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
     Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
     J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
     PubMed     Abstract available
     
     
     
252. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
     Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
     J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
     PubMed     Abstract available
     
     
     
253. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
     Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
     J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
     PubMed     Abstract available
     
     
     
254. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
     Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
     J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
     PubMed     Abstract available
     
     
     
255. COVEY TJ, Golan D, Sergott R, Wilken J, et al
     Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
     J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
     PubMed     Abstract available
     
     
     
256. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
     Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
     J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
     PubMed     Abstract available
     
     
     
257. TSAI CC, Jette S, Tremlett H
     Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
     J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
     PubMed     Abstract available
     
     
     
258. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
     The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
     J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
     PubMed     Abstract available
     
     
     November 2023
259. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
     Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
     J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
     PubMed     Abstract available
     
     
     
260. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
     Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
     J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
     PubMed     Abstract available
     
     
     
261. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
     Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
     J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
     PubMed     Abstract available
     
     
     
262. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
     COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
     J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
     PubMed     Abstract available
     
     
     
263. SUN Y, Li G, Liu X, Zhao X, et al
     Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
     J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
     PubMed     Abstract available
     
     
     
264. KENNEDY PGE, George W, Yu X
     The elusive nature of the oligoclonal bands in multiple sclerosis.
     J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
     PubMed     Abstract available
     
     
     
265. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
     SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
     J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
     PubMed     Abstract available
     
     
     
266. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
     Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
     J Neurol. 2023;270:5392-5397.
     PubMed     Abstract available
     
     
     
267. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
     Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
     J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
     PubMed    
     
     
     October 2023
268. MANTERO V, Cordano C, Balgera R, Basilico P, et al
     Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
     J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
     PubMed    
     
     
     
269. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
     Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
     J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
     PubMed     Abstract available
     
     
     
270. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
     Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
     J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
     PubMed     Abstract available
     
     
     
271. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
     Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
     J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
     PubMed     Abstract available
     
     
     
272. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
     Identification and management of subclinical disease activity in early multiple sclerosis: a review.
     J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
     PubMed     Abstract available
     
     
     
273. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
     Multiple sclerosis in the elderly: a retrospective cohort study.
     J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
     PubMed     Abstract available
     
     
     
274. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
     Multiple sclerosis: time for early treatment with high-efficacy drugs.
     J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
     PubMed     Abstract available
     
     
     
275. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
     Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
     J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
     PubMed     Abstract available
     
     
     
276. MANZANO GS, McEntire C, Venna N
     Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
     J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
     PubMed    
     
     
     
277. ZHANG Z, Wang Z, Du X, Huang X, et al
     Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
     J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
     PubMed    
     
     
     
278. KRAKER JA, Chen JJ
     An update on optic neuritis.
     J Neurol. 2023;270:5113-5126.
     PubMed     Abstract available
     
     
     
279. BRISCA G, Marini C, Buratti S, Mariani M, et al
     Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
     J Neurol. 2023;270:5034-5047.
     PubMed     Abstract available
     
     
     
280. WANG R, Sun D, Du Q, Shi Z, et al
     Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
     J Neurol. 2023;270:5085-5089.
     PubMed    
     
     
     September 2023
281. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
     Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
     J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
     PubMed     Abstract available
     
     
     
282. LI Y, Saul A, Taylor B, Ponsonby AL, et al
     Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
     J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
     PubMed     Abstract available
     
     
     
283. KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
     Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
     J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
     PubMed     Abstract available
     
     
     
284. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
     Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
     J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
     PubMed     Abstract available
     
     
     
285. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
     Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
     J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
     PubMed     Abstract available
     
     
     
286. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
     Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
     J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
     PubMed     Abstract available
     
     
     
287. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
     Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
     J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
     PubMed    
     
     
     
288. DI STEFANO V, Alonge P, Rini N, Militello M, et al
     Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
     J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
     PubMed     Abstract available
     
     
     
289. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
     Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
     J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.